Trimetazidine

Metabolic modulator

Antianginal metabolic efficiency; performance controversy

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Small molecule
Primary mechanism: Fatty-acid oxidation inhibition/glucose oxidation shift
Primary market use: Cardiology/performance risk

Pharmacology

Molecular weight (Da): 266.3
Oral bioavailability: ~90%
Half-life: ~6 h
Route tags: Route-dependent / verify
Evidence level: Approved outside US
Clinical status: Regulated/prohibited in sport
Value-for-money score: 6 / 10

Reported protocol signal

No popular protocol verified yet; keep as reference compound until protocol signal is added.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

Transient metabolic pharmacology

Sources

https://www.wada-ama.org/en/prohibited-list